Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Symbollon receives German regulatory input on IoGen program

March 5, 2007

Levemir approved in E.U. in combination with oral antidiabetic drugs

March 2, 2007

Jerini plans Q3 NDA submission for icatibant in HAE

March 2, 2007

PPD acquires exclusive license to novel Ranbaxy statin

March 2, 2007

Identification of ecallantide, an engineered, potent and selective inhibitor of plasma kallikrein

March 1, 2007

Oral salmon calcitonin begins phase III study in osteoporosis

March 1, 2007

Samaritan to market Elaprase in Greece and Cyprus

March 1, 2007

Recent patents disclose novel agents for obesity and disorders of lipid and bone metabolism

March 1, 2007

New agents for endocrine-related disorders imparted in recent patent literature

March 1, 2007

Positive phase I findings for LCP-AtorFen

Feb. 28, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...